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Glioblastoma is an exceptionally difficult cancer to treat. Cancer is universally marked by 
epigenetic changes, which play key roles in sustaining a malignant phenotype, in addition 
to disease progression and patient survival. Studies have shown strong links between the 
cellular redox state and epigenetics. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a 
redox-sensitive transcription factor that upregulates endogenous antioxidant production, 
and is aberrantly expressed in many cancers, including glioblastoma. Methylation of 
DNA and histones provides a mode of epigenetic regulation, and cobalamin-dependent 
reactions link the redox state to methylation. Antagonists of dopamine receptor 
subtype 4 (D4 receptor) were recently shown to restrict glioblastoma stem cell growth 
by downregulating trophic signaling, resulting in inhibition of functional autophagy. In 
addition to stimulating glioblastoma stem cell growth, D4 receptors have the unique ability 
to catalyze cobalamin-dependent phospholipid methylation. Therefore, D4 receptors 
represent an important node in a molecular reflex pathway involving Nrf2 and cobalamin, 
operating in conjunction with redox status and methyl group donor availability. In this 
article, we describe the redox-related effects of Nrf2, cobalamin metabolism, and the D4 
receptor on the regulation of the epigenetic state in glioblastoma.
Keywords: cobalamin, d4 dopamine receptor, glioblastoma, nrf2, dna methylation, glutathione, methionine 
synthase, transsulfuration
introdUCtion
Gliomas are the most common primary central nervous system (CNS) tumors in adults, accounting 
for 78% of all primary malignant CNS tumors (1). Glial tumors are classified based on the type of glial 
cell giving rise to the tumor as oligodendrogliomas (oligodendrocytes), ependymomas (ependymal 
cells), and astrocytomas (astrocytes). Astrocytomas, which account for most cases of glioma (1), can 
be ranked as low-grade (WHO grade I–II) or high-grade (WHO grade III–IV), depending on their 
clinical behavior and genetic features (2).
High-grade glioma (WHO grade IV) is typically divided into four subtypes: classical, neural, 
proneural, and mesenchymal (3). Classical glioblastoma presents with chromosomal abnor-
malities, including epidermal growth factor receptor (EGFR) mutation and/or increased EGFR 
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expression, but not protein 53 (p53) mutations (3). The neural 
subtype shares some similarities with the classical subtype, but 
frequently has p53 mutations and is positive for certain neuronal 
cell markers, such as neurofilament light peptide (NEFL) and 
gamma-aminobutyric acid receptor subunit α-1 (3). Proneural 
glioblastoma is associated with elevated plasma membrane levels 
of platelet-derived growth factor receptor and often have isoci-
trate dehydrogenase 1/2 (IDH1/2) mutations. The mesenchymal 
subtype uniquely displays activation of inflammatory mediators, 
especially NF-κB (3).
Surgical removal of primary glioblastoma is the preferred 
treatment option to prolong survival. While life expectancy 
can be prolonged by several months, the outcome is poor in the 
majority of patients who undergo resection because the tumor 
often continues to progress (4). At this time, there are two main 
non-surgical treatment protocols for glioblastoma. The first 
protocol comprises temozolomide, an orally administered DNA 
alkylating drug given in combination with radiation as first-line 
therapy (5). The second protocol comprises administration of 
the anti-angiogenic drug bevacizumab in patients with recurrent 
glioblastoma (6).
Despite treatment, the median survival time of patients 
with glioblastoma is between 9 and 12 months (1). A major 
cause of treatment failure is persistence of the epigenetic 
signatures, which define the malignant state (7). Epigenetic 
regulation provides dynamic control over gene expression. 
The methylation states of DNA and histones, which are 
influenced by intracellular S-adenosylmethionine (SAM) 
levels, are crucial determinants of this mode of regulation. 
DNA methylation at CpG sites promotes heterochromatin 
formation and gene silencing. Additionally, methylation of 
specific residues on the tails of histones, such as histone 3 
lysine residue 9 (H3K9me) and histone 3 lysine residue 27 
(H3K27me), can promote transcriptional silencing. However, 
other histone tail methylation marks, such as H3K4me, can 
lead to less dense nucleosome packing, thereby increasing 
promoter accessibility to transcription factors and favoring 
gene transcription.
Cancer is marked by genome-wide hypomethylation, 
chromosomal aberrations, and active transposable elements. 
Furthermore, cancer often presents with promoter hypomethyla-
tion or hypermethylation of genes expressing the components of 
major signaling pathways. The epigenetic landscape of glioblas-
toma includes differential expression patterns of long non-coding 
RNAs, such as increased HOTAIR (8). LncRNAs cooperate with 
proteins to modulate gene expression. Another typical epige-
netic feature of glioblastomas is upregulation of EZH2 (9), the 
catalytic component of polycomb repressive complex 2, that 
methylates H3K27 (histone 3 lysine residue 27) (9), leading to 
condensation of nucleosomes. Paradoxically, several proteins that 
promote gene expression are also overexpressed, such as BRD2 
(bromodomain-containing 2) and BRD4 (10). BRD2 and BRD4 
are members of the bromodomain and extra-terminal (BET) 
family of proteins, which recognize acetylated lysine residues 
on histones and promote transcription of the histone-associated 
genes. Additionally, certain lysine-specific demethylases (KDMs) 
and 5-methylcytosine hydroxylation enzymes, called ten-eleven 
translocation (TET) enzymes, are inhibited by oncometabolites, 
such as 2-hydroxyglutarate (2-HG) and succinate (11).
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a tran-
scription factor activated during oxidative stress that upregulates 
the expression of genes involved in antioxidant production. 
Glioblastoma and numerous other cancers are characterized 
by aberrant Nrf2 expression. Methylcobalamin (MeCbl) and 
5′-deoxyadenosylcobalamin (AdoCbl)—the active forms of 
cobalamin (vitamin B12)—play central roles in regulating DNA 
and histone methylation by serving as cofactors for methionine 
synthase (MS) and methylmalonyl-CoA mutase (MCM), 
respectively. Their levels are sensitive to the cellular antioxidant 
status, making them responsive to Nrf2. The dopamine receptor 
subtype 4 (D4 receptor) is a G protein-coupled receptor (GPCR) 
with neurotransmission and metabolic roles, which include 
effects on the redox and methylation states. D4 receptors are 
expressed in glioblastoma and D4 receptor antagonists inhibit 
the growth of glioblastoma stem cells (12), although the precise 
relationship between Nrf2 and D4 receptors has not yet been 
established. This article is the first to explore the relationships 
between Nrf2, cobalamin, and D4 receptors in cancer, specifically 
in glioblastoma. Recognition of these relationships opens new 
opportunities for identifying novel drug targets.
tHe roLe oF nrf2 in CanCer and 
GLioBLastoMa
Nuclear factor (erythroid-derived 2)-like 2 is a cap-n-collar basic 
region leucine zipper transcription factor. Under normal condi-
tions, Nrf2 is sequestered through its Neh2 domain by a ubiquitin 
ligase substrate adaptor called Kelch-like ECH-associated protein 
1 (Keap1) (13) (Figure 1). Upon interacting with electrophiles, 
such as reactive oxygen species (ROS), Keap1 releases Nrf2, 
which relocates to the nucleus, where it heterodimerizes with 
musculoaponeurotic fibrosarcoma proteins and binds to antioxi-
dant response elements (AREs) with the core consensus sequence 
5′-TGACnnnGC-3′ (14). In this way, Nrf2 regulates ≥1% of 
genes (15). ARE-regulated genes are typically involved in the 
production of antioxidants (e.g., glutathione) and detoxification 
enzymes (e.g., glutathione peroxidase 2).
Nuclear factor (erythroid-derived 2)-like 2 acts as a tumor 
suppressor or an oncoprotein (16), depending upon the nature 
of the cell expressing it. In normal physiologic conditions, Nrf2 
activation is brief and its transcriptional effects can restore 
redox homeostasis (13). The tight regulation of Nrf2 reduces 
the risk of cellular transformation from a benign state to a 
malignant state, reflecting its status as a tumor suppressor 
in typical cells. This tumor-suppressing effect is attributed 
to the ability of Nrf2 to decrease ROS levels and to restrict 
DNA damage by promoting the expression of antioxidant and 
detoxification systems (13). Although Nrf2 generally suppresses 
cellular transformation, it may actually enhance this process 
in some situations. This appears to be the case in BEAS-2B 
lung bronchial epithelial cells chronically exposed to the 
metal cadmium (17). In these cells, Nrf2 binds to AREs on 
the antiapoptotic genes Bcl-2 and Bcl-xL and to an ARE at p62, 
FiGUre 1 | nrf2-dependent transcription of genes promoting GsH synthesis. Oxidative stress induces the dissociation of Nrf2 from cytosolic Keap1, 
allowing its relocation to the nucleus where it augments the transcription of multiple genes directly or indirectly involved in GSH synthesis (dashed arrows), thereby 
increasing antioxidant capacity. Nrf2 activation of GSH synthesis negatively affects the methylation capacity by promoting transsulfuration of homocysteine to 
cysteine. Abbreviations: CBS, cystathionine-β-synthase; CGL, cystathionine-γ-lyase, EAAT3, excitatory amino acid transporter-3; GCLM, γ-glutamylcysteine ligase 
modulatory subunit; GR, glutathione reductase; GSH, glutathione; GSS, glutathione synthetase; GSSG, glutathione disulfide; G6PD, glucose-6-phosphate 
dehydrogenase; Keap1, kelch-like ECH-associated protein 1; Maf, musculoaponeurotic fibrosarcoma proteins; MAT, methionine adenosyltransferase; MS, 
methionine synthase; MT, methyltransferase; Nrf2, nuclear factor (erythroid-derived 2)-like 2; SAHH, S-adenosylhomocysteine hydrolase.
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which codes a ubiquitin-binding protein (17). Phosphorylated 
p62 maintains constitutive Nrf2 activity in transformed cancer 
cells, such as transformed BEAS-2B cells, by binding to Keap1 
and blocking its suppressive interaction with Nrf2 (17, 18). 
Consequently, the transcription of ARE-containing genes is 
increased and loses responsiveness to intracellular redox status 
in malignant cells. In this setting, Nrf2 promotes tumor cell 
proliferation by acting as an oncoprotein and increasing tumor 
resistance to chemotherapy and radiation (19).
The expression of Nrf2-regulated genes is essential for the 
survival of many cancer types because high levels of ROS are 
produced during cell growth, implying that cancer cells are 
burdened with higher levels of ROS than non-neoplastic cells 
(20). Higher ROS levels can impair enzyme function, and several 
enzymes involved in epigenetic regulation are especially sensitive 
to ROS, including enzymes discussed in this article: MS, MCM, 
histone deacetylases (HDACs) 2 and 4 (HDAC2/4) (21, 22), and 
propionyl-CoA carboxylase (23).
Mitochondrial respiration is a major source of ROS produc-
tion and increased antioxidant capacity secondary to Nrf2 
activation increases mitochondrial aerobic activity, while Nrf2 
interaction with other transcriptional factors increases mito-
chondrial biogenesis. Indeed, Nrf2 and Keap1 are tethered to the 
outer mitochondrial membrane phosphatase phosphoglycerate 
mutase family member PGAM5, representing a third site of 
distribution (beyond cytoplasmic and nuclear) (24). PGAM5 
degradation is in turn regulated by a Keap1-dependent ubiquitin 
ligase complex (25), indicating that Nrf2/Keap1 and mitochon-
drial activities are coordinated.
Nuclear factor (erythroid-derived 2)-like 2 is overexpressed 
in glioblastoma (26) and elevated expression of genes under the 
transcriptional influence of Nrf2 occurs in 13.7 and 32.7% of 
anaplastic gliomas and glioblastomas, respectively (27). There is 
a strong connection between ROS (and other radicals) and the 
epigenetic mechanisms that regulate gene expression. Because 
Nrf2 is a central regulator of the intracellular balance between 
antioxidants and free radicals, its overexpression may account 
for much of the epigenetic divergence of glioblastoma from its 
precursor cells.
nrf2, antioXidants, and CoBaLaMins
Cobalamin is a corrin ring-containing structure with a central 
cobalt atom. Different cobalamin species have a variable upper 
axial ligand bound to the cobalt, enabling cobalamin to act as 
a cofactor for two enzymes in humans. MeCbl is utilized by 
MS, while AdoCbl is necessary for the activity of MCM. Cobalt 
contributes to the propensity of cobalamin to be a highly potent 
reducing agent, and thus an easily oxidized molecule.
For cobalamin to be converted into its active forms, the cobalt 
atom must be in its (II) transition state (28). This is achieved enzy-
matically after the cellular uptake of cobalamin in a complex with 
transcobalamin, a cobalamin-carrier protein (29). The complex is 
initially imported into cells via the transcobalamin receptor (30). 
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As cobalamin accumulates in tumors (31), both transcobalamin 
and transcobalamin receptor have been explored as potential 
tumor biomarkers and their expression is elevated in numerous 
canine and feline cancers (32). Cobalamin exits lysosomes and 
interacts with a cytoplasmic enzyme, methylmalonic aciduria, 
and homocystinuria type C protein (MMACHC), that removes 
the upper axial ligand and reduces the cobalt atom to its (II) 
oxidized state (29). To accomplish this, MMACHC uses NADPH 
to remove cyano groups (from cyanocobalamin) and reduced 
glutathione (GSH) to remove methyl and adenosyl groups (33).
The potential for Nrf2 to regulate cobalamin status is related 
to its ability to transcriptionally activate enzymes involved in 
regulating the intracellular concentrations of the metabolic 
reducing agents (i.e., GSH and NADPH), which are necessary 
to process and protect cobalamins. Indeed, Nrf2 may be a key 
factor that increases the cobalamin content of glioblastoma cells 
in response to activation of the phosphoinositide 3-kinase (PI3K) 
or extracellular signal-regulated kinase (ERK) pathway induced 
by growth factor receptor signaling, irrespective of whether these 
pathways are stimulated by their respective ligands or transacti-
vated by D4 receptors (34). Of note, some mutations may result 
in hyperactivity of these transduction pathways (Figure  2). In 
SH-SY5Y neuroblastoma cells, stimulation of the PI3K pathway 
by the growth factor neuregulin-1 was associated with increased 
intracellular concentrations of cobalamin owing to activation 
of the cysteine transporter excitatory amino acid transporter-3 
(EAAT3) (35). EAAT3 translocation to the plasma membrane 
in response to PI3K activation is associated with an increase in 
GSH, and Nrf2 is a known transcriptional activator of EAAT3 
(36). PI3K and ERK are known to promote the activity of Nrf2 
in glioblastoma (37), which may increase cobalamin levels by 
upregulating NADPH and GSH.
Excitatory amino acid transporter-3 levels are increased by 
neuregulin-1 in C6 glioma cells (38), a cell line that serves as a 
useful model for the study of glioblastoma. The cystine/glutamate 
antiporter, also known as system Xc−, provides an important 
source of cysteine for GSH synthesis, as cystine is reduced to two 
cysteine molecules in the cytoplasm. Nrf2 induces transcription 
of xCT (SLC7A11), a component of Xc−, along with other GSH 
synthesis and redox-related genes (Table 1).
Epidermal growth factor receptor activation in C6 glioma cells 
upregulates xCT in association with increased GSH levels (48). In 
mice, EGFR-overexpressing gliomas are associated with greater 
invasiveness, and the xCT inhibitor sulfasalazine suppressed 
tumor growth and invasiveness. Taken together, these findings 
suggest that increased EGFR signaling may increase xCT and 
GSH synthesis via increased Nrf2 expression, contributing to the 
aggressive properties of glioblastoma.
nrf2, saM, and GLioBLastoMa
Many biological processes are regulated by methylation reac-
tions, including DNA and histone methylation. These reactions 
are governed by the availability of the universal methyl donor 
SAM, and methyltransferases are inhibited by the demethyl-
ated end-product S-adenosylhomocysteine (SAH). The SAM 
to SAH ratio is affected by the kinetics of the cobalamin- and 
folate-dependent enzyme MS, which converts homocysteine to 
methionine.
While normal cells can adapt to a lack of methionine, many 
cancer cell lines require methionine, as demonstrated by their 
inability to survive just on methionine provided by MS activity 
(i.e., methionine derived from homocysteine) (49). While the 
cause of this condition varies, it may reflect a limitation in cobala-
min or folate availability. By contrast, methionine-independent 
cancer cells can maintain sufficient levels of MS activity and 
methionine synthesis to sustain their rapid growth rates.
By augmenting GSH synthesis, Nrf2 activity can influence 
methionine dependence and the cell’s methylation state in multi-
ple ways. As illustrated in Figure 3, left panel, the normal adaptive 
response to oxidative stress involves a transient increase in Nrf2 
activity together with a decrease in the ratio of reduced GSH to 
oxidized glutathione disulfide (GSSG) (i.e., [GSH]2/[GSSG]). 
Increased transcription of ARE-regulated genes serves to aug-
ment antioxidant capacity, restoring redox status and allowing 
Nrf2 activity to return to its basal level. However, methylation 
activity decreases during periods of elevated oxidative stress, 
affecting DNA and histone methylation, with the potential for 
persistent epigenetic effects.
The potential for DNA mutations increases during transient 
oxidative stress (due to unquenched oxidizing species) and/or 
increased prevalence of euchromatin (non-compacted DNA). 
Cancer-inducing mutations in pathways controlling Nrf2 expres-
sion (e.g., PI3K) during repetitive or unresolved periods of 
oxidative stress can lead to constitutive Nrf2 activation (Figure 3, 
middle panel). Unlike in normal physiologic conditions, muta-
tion-induced Nrf2 overexpression is not transient and can lead 
to an abnormally high antioxidant capacity, which promotes cell 
division and produces an abnormal pattern of DNA and histone 
methylation.
As illustrated in Figure  3 (right panel), sustained Nrf2 
hyperactivity induced by mutations can promote methionine-
independent or methionine-dependent phenotypes, depending 
on the level of MS activity. Under conditions where the increase 
in cystine/cysteine uptake is dominant, MS-mediated meth-
ylation of homocysteine is maintained, resulting in methionine 
independence. However, when the increase in transsulfuration 
of homocysteine toward GSH production is more dominant, 
MS activity is insufficient, resulting in methionine dependence. 
Thus, the balance between cystine/cysteine uptake and homo-
cysteine transsulfuration is a major determinant of methionine 
dependence.
Increased cystine/cysteine uptake capacity secondary to Nrf2 
activation may have implications on the tumor microenviron-
ment. Increased expression of Xc− and EAAT3 enhances tumor 
uptake of antioxidant resources at the expense of other cells in 
the microenvironment. Glioblastoma cells may competitively 
impinge on EAAT3-dependent cysteine uptake by neuronal cells, 
with potential functional implications for neurons.
Nuclear factor (erythroid-derived 2)-like 2 can also affect MS 
activity by influencing cobalamin synthesis and cellular redox sta-
tus. As described above, Nrf2 can promote cobalamin assimilation 
FiGUre 2 | nrf2 regulation of cobalamin metabolism. Nrf2 upregulates Xc− and EAAT3 transcription, increasing cysteine availability for GSH synthesis. Nrf2 
also upregulates the formation of GSH and NADPH, promoting MMACHC-dependent conversion of cobalamin to its active forms (MeCbl and AdoCbl). Mutations in 
PI3K- and ERK-linked trophic receptors (e.g., epidermal growth factor receptor and platelet-derived growth factor receptor beta), can increase their activities, 
augmenting cystine/cysteine uptake and increasing the levels of active cobalamin species, with epigenetic consequences. Transactivation of PDGFR by the D4 
receptor also promotes PI3K/ERK signaling and cystine/cysteine uptake. Abbreviations: 2-OG, 2-oxoglutarate; AdoCbl, adenosylcobalamin; Cbl, cobalamin; EAAT3, 
excitatory amino acid transporter-3; GSH, glutathione; GSSG, glutathione disulfide; MeCbl, methylcobalamin; MMACHC, methylmalonic aciduria and homocystinuria 
type C protein; Nrf2, nuclear factor (erythroid-derived 2)-like 2; PI3K, phosphoinositide 3-kinase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
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through its ability to increase GSH and NADPH level, and the 
resultant increase in cobalamin availability decreases methio-
nine dependency by sustaining MS activity (50). In addition, a 
Nrf2-induced decrease in oxidative stress status decreases the 
frequency of cobalamin inactivation and promotes MS activity. 
When the cobalt atom of the cobalamin cofactor of MS is in its (I) 
oxidation state, it removes and transiently holds a methyl group 
from 5-methyltetrahydrofolate. The methyl group is subsequently 
transferred to homocysteine, forming methionine. However, 
cobalamin (I) is readily oxidized, depending upon the prevailing 
redox environment, temporarily halting enzyme activity, until 
it is reactivated by NADPH-dependent MS reductase. Thus, 
hyperactivity of Nrf2 decreases the rate of cobalamin oxidation 
by lowering oxidative stress and ROS levels, and facilitates MS 
reactivation by promoting higher levels of NADPH.
The availability of methionine is proportionally reflected by 
intracellular SAM concentrations (51). Therefore, the involve-
ment of Nrf2 in maintaining a methionine-independent state 
may dictate how glioblastoma cells allocate SAM toward different 
reactions. SAM-dependent methylation reactions in the nucleus 
control gene expression through multiple mechanisms. Thus, the 
availability of SAM, as modulated by Nrf2, may affect the survival 
FiGUre 3 | redox-dependent epigenetic regulation and oncogenesis. Left panel: transient Nrf2 activation is an important component of the adaptive 
metabolic responses to oxidative stressors, accompanied by epigenetic changes, which promote homeostatic restoration of redox equilibrium. Middle panel: 
multiple oxidative challenges increase the potential for DNA mutations, including mutations of growth factor signaling pathway components, which can lead to 
sustained Nrf2 activation, resulting in abnormal redox and epigenetic status. Right panel: methionine-independent and methionine-dependent states can 
alternatively emerge from oncogenesis, depending upon the level of MS activity, which is influenced by the ratio of cystine/cysteine uptake vs. transsulfuration. 
Abbreviations: GSH, glutathione; GSSG, glutathione disulfide; MS, methionine synthase; Nrf2, nuclear factor (erythroid-derived 2)-like 2.
taBLe 1 | Genes and corresponding proteins regulated by nrf2.
Gene protein/enzyme name role reference
SLC1A1 Excitatory amino acid transporter 3 Cysteine transporter, usually associated with neurons (36)
GCLC γ-glutamylcysteine ligase (catalytic subunit) Subunits of the rate-limiting enzyme for GSH production (39)
GCLM γ-glutamylcysteine ligase (modifier subunit)
TXNRD1 Thioredoxin reductase Selenoprotein in thioredoxin antioxidant pathway (40, 41)
G6PD Glucose-6-phosphate dehydrogenase Pentose phosphate pathway enzyme that maintains reduced NADPH (42)
SLC7A11 xCT subunit of amino acid transporter system Xc− Cystine transporter in astroglial cells (43, 44)
HSP70 Heat shock protein 70 Cellular stress response protein (45)
HSP40 Heat shock protein 40
MTHFD2 Methylenetetrahydrofolate dehydrogenase 2 Purine synthesis (46)
IDH1 Isocitrate dehydrogenase 1 Converts isocitrate to 2-oxoglutarate, regenerating NADPH (47)
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and proliferation of glioblastoma cells by influencing genome-
wide gene transcription.
In addition to its role in DNA and histone methylation, SAM 
is used for the synthesis of polyamines, which are involved in 
cell growth, transcription, translation, and numerous other 
processes (52). Indicative of the importance of polyamines in 
cancer, a polyamine analog was reported to induce apoptosis in 
glioblastoma cells by exhausting the cellular polyamine content 
(53). Polyamines are recycled back into the one-carbon cycle as 
methylthiooxobutyrate to re-form methionine and subsequently 
SAM. SAM may also influence many processes involved in the 
progression of glioblastoma, including cell signaling, cell cycle 
progression, protein translation, mRNA splicing, and possibly the 
health of telomeres (54).
Finally, SAM may influence glioblastoma by acting as a 
positive allosteric modulator of proteins involved in maintaining 
redox homeostasis, including cystathionine-β-synthase (CBS) 
and Nrf2. CBS is one of two Nrf2-regulated enzymes in the trans-
sulfuration pathway. This pathway directs homocysteine away 
from the one-carbon cycle toward cysteine synthesis, accompa-
nied by α-ketobutyrate formation (Figure  1). Notably, Nrf2 is 
post-translationally methylated at an arginine residue (R437) in 
its Neh1 domain by the arginine methyltransferase PRMT1 (55). 
R437 methylation of Nrf2 increases its DNA-binding ability and 
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increases recruitment of transcriptional coactivator p300/CBP 
(CREB-binding protein) to an ARE in the heme oxygenase-1 pro-
moter region. However, expression of both Nrf2 and its suppres-
sor keap1 are also subject to epigenetic regulation by promoter 
methylation in several cancers types (56). Thus, the relationships 
between Nrf2, SAM, and glioblastoma are highly complex.
nrf2 and onCoMetaBoLites in 
GLioBLastoMa
Oncometabolites are metabolic intermediates that promote 
tumor growth and other malignant processes. These oncogenic 
metabolites are either produced excessively or are inefficiently 
metabolized in cancer and consequentially accumulate in the 
cytosol (57). Well-known examples of oncometabolites include 
succinate and fumarate. Mutations in succinate dehydrogenase 
(SDH) and fumarate hydratase prevent the passage of their 
respective substrates, succinate and fumarate, through the Krebs 
cycle, resulting in their accumulation. Mutations in these proteins 
have been linked to malignant pheochromocytoma, paragan-
glioma, and other forms of cancer (58–60). When mutated in 
glioblastoma, IDH1/2 yield another oncometabolite, 2-hydroxy-
glutarate (2-HG), from 2-oxoglutarate (2-OG) (also known as 
α-ketoglutarate) (61). While mutations in IDH1/2 are clinically 
relevant (62), only IDH1 is transcriptionally regulated by Nrf2.
Because Nrf2 enhances cobalamin processing, and thus 
AdoCbl levels, it can connect the transsulfuration pathway to 
the Krebs cycle. AdoCbl promotes the formation of succinate. 
As a cofactor for the mitochondrial enzyme MCM, AdoCbl is 
necessary for the catabolism of certain fats and amino acids in a 
pathway involved in the anaplerotic incorporation of succinate 
into the Krebs cycle as succinyl-CoA, which is then converted 
to succinate.
The amino acid methionine is catabolized through this 
anaplerotic pathway. The passage of methionine through the 
one-carbon cycle produces homocysteine, and any homocysteine 
that is not recycled back to methionine can enter the transsulfura-
tion pathway and be converted to cystathionine. Cystathionine 
is then converted to cysteine and α-ketobutyrate. While 
cysteine is directed toward GSH production, α-ketobutyrate is 
converted to propionyl-CoA, which is subsequently converted 
to d-methylmalonyl-CoA by the biotin-dependent enzyme pro-
pionyl-CoA carboxylase. d-methylmalonyl-CoA is converted to 
l-methylmalonyl-CoA by epimerase, and MCM (with its AdoCbl 
cofactor) converts l-methylmalonyl-CoA to succinyl-CoA.
The product of this pathway, succinyl-CoA, enters the Krebs 
cycle and is converted to succinate by succinyl-CoA synthetase. 
Succinate is subsequently converted to fumarate by SDH, or com-
plex II of the mitochondrial electron transport chain. Fumarate 
and succinate can act as retrograde signaling messengers, relaying 
information from the mitochondria through their influence over 
epigenetics and cell signaling. Both fumarate (63) and succinate 
(64) inhibit prolyl hydroxylases from ubiquitinating hypoxia-
inducible factor-1α (HIF-1α) and allow its buildup in normoxic 
conditions. However, only fumarate binds to cysteine residues on 
keap1, increasing the amount of Nrf2 available to promote gene 
transcription (65). SDH subunit B was downregulated and HIF-
1α was expressed in glioblastoma stem cells in normoxic condi-
tions (66). However, certain glioblastoma-associated mutations 
promote oxidative phosphorylation rather than glycolysis (67). 
Therefore, the amount of succinate and fumarate in glioblastoma 
cells may vary according to how closely they resemble a stem 
cell phenotype and the presence of specific mutations in energy 
producing pathways, in addition to AdoCbl levels; factors that 
may be influenced by Nrf2.
Nuclear factor (erythroid-derived 2)-like 2 can increase the 
level of 2-HG, another retrograde signaling molecule in glioblas-
toma. 2-HG is produced by mutant forms of IDH1/2. Normally, 
IDH1/2 promote the conversion of isocitrate to 2-OG, while 
reducing NADP+ to NADPH. However, mutated forms of IDH1/2 
convert 2-OG to 2-HG. Furthermore, these mutant forms oxidize 
NADPH to NADP+. Ordinarily, the expression of IDH2 (the 
mitochondrial isoform) is not directly induced by Nrf2. However, 
the activity of mutated IDH2 may be indirectly promoted by Nrf2 
through the increased concentration of NADPH. Around 80% 
of low-grade gliomas and 5–10% of glioblastomas have IDH1/2 
mutations (3) and display increased methylation in the gene 
promoters compared with other glioma subtypes.
epiGenetiC eFFeCts oF 2-HG, 
sUCCinate, and FUMarate
Epigenetic control of gene expression is mediated by numerous 
regulatory factors and represents an overlaying program that 
governs the manner in which the genetic code is read. Specifically, 
epigenetic alterations determine the probability of gene expres-
sion, the timing of expression, and which isoforms of a specific 
gene are produced. One of the most important epigenetic events is 
the chemical modification of amino acid residues in histone tails 
by ubiquitin, acetyl, phosphoryl, and methyl groups. Histone tail 
methylation marks are laid down by histone methyltransferases. 
These marks include H3K4me (which leads to chromatin open-
ing and is positively associated with gene expression), as well as 
H3K9me and H3K27me (which lead to chromatin condensation 
and are associated with inactivation of gene expression).
Histone lysine demethylases (KDMs) remove methyl groups 
from lysine residues on histone tails. There are two classes of 
KDMs: 2-OG-dependent dioxygenases (2-OGDOs), which pos-
sess Jumonji C domains, and flavin-containing amino oxidases. 
2-OGDOs can oxidize numerous substrates, which are not lim-
ited to methylated lysine and cytosine residues (68). 2-OGDO 
enzymes convert 2-OG to succinate and CO2. 2-OGDO activity 
is downregulated in a negative feedback loop by succinate, fuma-
rate, and by 2-HG (68).
KDM2-7 are inhibited by the same, whereas KDM1a belongs to 
the flavin-containing amino oxidase subclass and is not inhibited 
by these oncometabolites. KDM1a regulates the transcription 
of embryonic transcription factors by altering Myc expression 
(69). The role of KDM1a in removing histone tail methylation 
marks may become more prominent following oncometabolite-
mediated inhibition of KDM2-7. Although KDM2-7 are sensitive 
to succinate, fumarate, and 2-HG, KDM1a activity is regulated 
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by flavin adenine dinucleotide. The reaction mediated by SDH 
results in the conversion of succinate to fumarate, in which flavin 
adenine dinucleotide is used as a cofactor to accept two hydrogen 
atoms and two electrons. Therefore, SDH may act as a junction 
that regulates both KDM1a and KDM2-7. However, more stud-
ies are needed to elucidate the dynamics between SDH, KDM1a, 
KDM2-7, and histone tail marks in glioblastoma.
Other members of the 2-OGDO family include the TET 
enzymes. TET enzymes catalyze the first step of cytosine 
nucleotide demethylation by converting 5-methylcytosine to 
5-hydroxymethylcytosine (5hmeC) (70). This step is essential 
for demethylating CpG sites to allow gene reactivation because 
methyl-binding proteins cannot block access to transcriptional 
machinery following demethylation.
Like KDM2-7, TET1-3 are inhibited by succinate, fumarate, 
and 2-HG. The levels of 5hmeC are low in many cancers, includ-
ing glioblastoma. A deficit in 5hmeC may indicate a significant 
reduction in TET enzyme activity that might arise from gene 
deletions or mutations (71). However, genetic sequencing does 
not support the hypothesis that mutations are a major causal fac-
tor of 5hmC depletion in colorectal, breast, and prostate cancer 
(72). The expression of mutant IDH1 in the subventricular zone 
of mice was associated with decreased 5hmeC genomic content 
and increased 5-methylcytosine levels, mimicking gliomagen-
esis (73). Therefore, it is plausible that oncometabolite-mediated 
inhibition of TET activity contributes to the reduced 5hmeC 
expression observed in these cancers and in glioblastoma.
redoX and transCriptionaLLy 
indUCed epiGenetiC eFFeCts oF nrf2
Nuclear factor (erythroid-derived 2)-like 2 can exert epigenetic 
effects via multiple mechanisms. As described in the Section 
“The Role of Nrf2 in Cancer and Glioblastoma,” Nrf2 influences 
the transcription of ARE-containing genes to increase the levels 
of antioxidants and 2-HG (in IDH1 mutants). This increase in 
antioxidant levels protects cobalamin from oxidation, sustain-
ing the one-carbon cycle. Antioxidants also protect the enzyme 
propionyl-CoA carboxylase, which is upstream of MCM in an 
anaplerotic pathway that leads to the formation of succinate. The 
metabolic information conveyed by the intracellular concentra-
tions of SAM and the oncometabolites succinate and 2-HG is 
integrated at the nucleus and determines global DNA and histone 
methylation and demethylation.
While Nrf2 indirectly regulates epigenetics through chemical 
messengers, such as succinate and 2-HG, it can also regulate epi-
genetics in a more direct manner. Many epigenome-modifying 
proteins are sensitive to the intracellular redox balance, the prime 
examples being HDACs 2 and 4 (21, 74). HDACs remove acetyl 
groups from histone tail residues and non-histone proteins, thereby 
decreasing gene transcription. HDAC4 expression is downregu-
lated in glioblastoma compared with other gliomas and normal 
brain tissue, although there is considerable variation in its expres-
sion levels between resected tumors from glioblastoma patients 
and other gliomas (75). The protective effect of Nrf2 on HDAC4 
was reported to precede HDAC4-mediated downregulation of 
the microRNAs miR-206 and miR-1 in lung and prostate cancer 
cell lines (22). Downregulation of these microRNAs by HDAC4, 
downstream of Nrf2, increased the expression of Krebs cycle and 
pentose phosphate pathway components. These findings support 
the hypothesis that the epigenetic effects of Nrf2 have redox and 
metabolic consequences.
d4 reCeptors, MetHyLation, and 
GLioBLastoMa
Dolma et  al. (12) recently reported that selective D4 receptor 
antagonists restrict the growth of glioblastoma stem cells in vitro 
and in  vivo. Clonogenic activity of freshly isolated tumor cells 
was reduced 19- to 83-fold by these antagonists. Analysis of 
gene expression in cells exposed to a D4 receptor antagonist 
revealed significant changes in lipid/cholesterol biosynthetic, 
autophagic vacuole, and lysosomal pathways, leading massive 
accumulation of autophagic vacuoles and cholesterol owing to 
decreased autophagic flux and disrupted lysosomal function. 
These glioblastoma stem cell-specific effects were accompanied 
by decreased phosphorylation of multiple proteins, including 
platelet-derived growth factor receptor beta (PDGFRβ), which 
was previously shown to be transactivated by D4 receptor stimula-
tion (34). Indeed, transactivation of PDGFRβ and its downstream 
signaling target ERK1/2 by the D4 receptor may contribute to 
increased Nrf2 activity, as described above, while D4 receptor 
antagonists have opposite effects. Since PDGFRβ levels are 
increased in proneural glioblastoma, more robust D4 receptor 
co-activation may be particularly important in this subtype. The 
inhibitory effects of D4 receptor antagonists were synergistic with 
those of temozolomide, and poorer survival rates were observed 
for tumors with greater D4 receptor expression.
Although the study by Dolma et al. (12) showed that the D4 
receptor is an important new antitumor target for glioblastoma, the 
detailed molecular mechanism underlying its unique autophagy-
based effectiveness remain unclear. Like other GPCRs, the D4 
receptor exerts several G protein-mediated signaling activities, 
including inhibition of cyclic AMP formation. However, only the 
D4 receptor is involved in dopamine-dependent methylation of 
membrane phospholipids (76). This exclusive activity arises from 
a methionine residue (MET313) in transmembrane helix #6 of the 
D4 receptor, not present in other GPCRs, a locus that undergoes a 
large change in position in response to agonist occupation of the 
binding site (77). This dopamine-induced conformational change 
facilitates ATP-dependent S-adenosylation of the MET313, fol-
lowed by transfer of its methyl group to adjacent phospholipids, 
especially phosphatidylethanolamine (78). After methyl transfer 
and removal of the adenosyl group, a replacement methyl group 
is provided to the resulting homocysteine form of the receptor by 
MS, in a cobalamin/methylfolate-dependent reaction, complet-
ing a cycle of dopamine-stimulated phospholipid methylation 
(PLM).
Notably, the cycle of D4 receptor-mediated PLM utilizes the 
same enzymes that support SAM-dependent methylation reac-
tions (76), placing the D4 receptor in the position of regulating 
all methylation reactions in a dopamine-dependent manner, as 
FiGUre 4 | d4 receptor interaction with Ms. Conformation-dependent exposure of the methionine residue in the D4 receptor allows it to catalyze phospholipid 
methylation (PLM), which is dependent upon folate-derived methyl groups supplied by MS. D4 receptor antagonists stabilize the inactive conformation and sequester 
MS, while D4 receptor agonists such as dopamine promote PLM and increase MS-dependent conversion of HCY to MET. Abbreviations: D4R, D4 receptor; HCY, 
homocysteine; MET, methionine; MS, methionine synthase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine.
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illustrated in Figure 4. Indeed, D4 receptor-mediated stimulation 
of MS activity and increased global DNA methylation have been 
reported in human neuroblastoma cells (79), and these effects 
were blocked by inhibitors of the PI3K and ERK signaling path-
ways. It remains to be determined whether D4 receptors exert a 
similar influence in glioblastoma.
Based on the unique capability of the D4 receptor to modulate 
methylation status, we suggest that the anti-glioblastoma tumor 
effects of D4 receptor antagonists described by Dolma et  al. 
(12) may reflect inhibition of methylation reactions such as 
dopamine-stimulated PLM, which can influence the activity of 
receptors and transporters at the plasma membrane (80), and/or 
SAM-dependent methylation effects, which might include effects 
on autophagy. For example, increased membrane fluidity and/or 
membrane asymmetry promoted by D4 receptor-mediated PLM 
may contribute to PDGFRβ transactivation. PLM-related phos-
pholipid adducts were also reported to play crucial regulatory 
roles in promoting mitophagy, a specialized form of autophagy 
(81). At high levels, methionine and SAM act as indicators of 
amino acid sufficiency and suppress autophagy (82). This hypoth-
esis is supported by the finding that autophagy was attenuated 
by short hairpin RNA-mediated knockdown of MS reductase in 
SKOV3 and cisplatin-resistant SKOV3/DDP cells (83). Studies of 
dopamine-stimulated PLM may help our understanding of how 
the D4 receptor regulates autophagy in glioblastoma stem cells.
potentiaL treatMent tarGets
Despite the development of temozolomide and bevacizumab, 
glioblastoma invariably has a poor prognosis, necessitating the 
development of more effective therapies. Several classes of drugs 
are being explored, including many that target the epigenetic 
landscape. Some epigenetic modifiers, such as BET proteins, 
are overexpressed in glioblastoma. Because BET proteins are 
indispensable for glioblastoma growth (10), BET inhibitors are 
an important area of research. JQ1 is a BET inhibitor that caused 
G1 cell cycle arrest and apoptosis in several glioblastoma cell 
lines, which were genetically modified to resist cell death (84). 
However, JQ1 has a short half-life, limiting its utility in glio-
blastoma treatment (85). Another BET inhibitor, OTX015, has 
entered dose optimization trials for glioblastoma therapy (http://
ClinicalTrials.gov Identifier NCT02296476).
Histone deacetylases inhibitors have been also tested in glio-
blastoma (86), although their clinical use is generally limited to 
FiGUre 5 | an interactive network of the redox and methylation factors contributing to the glioblastoma phenotype. Abbreviations: ERK, extracellular 
signal-regulated kinase; GSH, glutathione; GSSG, glutathione disulfide; Nrf2, nuclear factor (erythroid-derived 2)-like 2; PI3K, phosphoinositide 3-kinase.
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certain lymphomas. HDAC inhibitors reactivate the expression 
of genes, which either promote cell death or improve the efficacy 
of other drugs. For example, HDAC inhibitors can restore the 
expression of estrogen receptor α (ERα) in ERα negative breast 
cancer, potentially re-allowing the administration of tamoxifen 
to tumors that had become non-responsive to antiestrogen 
drugs (87). However, a concern of using HDAC inhibitors for 
treating glioblastoma is that they might re-activate expression of 
O6-alkylguanine DNA alkyltransferase (MGMT), a DNA repair 
methyltransferase associated with temozolomide resistance (88).
An interesting approach to circumvent the risk of re-activating 
MGMT in glioblastoma is to administer drugs capable of modu-
lating the redox capacity, such as the flavonoid luteolin. Luteolin 
was reported to reduce Nrf2 mRNA and protein levels in tumors 
(89), thus affecting redox and epigenetic regulation. Owing to 
the antioxidant-boosting and antiapoptotic effects of Nrf2, 
the benefits of a Nrf2 inhibitor may outweigh any risks posed 
by altering the epigenetic signature it imparts to glioblastoma 
cells. Treatment of A549 cells with luteolin enhanced the 
cytotoxicity of doxorubicin, oxaliplatin, and bleomycin (89). 
Furthermore, a combination of luteolin and another flavo-
noid, silibinin, caused autophagy and apoptosis by inhibiting 
protein kinase Cα (PKCα) and inducible nitric oxide synthase 
(iNOS), respectively, in U87MG and T98G glioblastoma cells 
(90). Additionally, luteolin is considered to be neuroprotective 
and was ironically demonstrated to induce Nrf2 activity in a 
mouse model of traumatic brain injury (91). Therefore, this 
phytochemical may selectively target neoplastic tumor cells and 
protect surrounding brain tissue.
Because cystine transporter activity is upregulated in 
glioblastoma (48), selective transporter inhibitors might be 
useful treatment options. Indeed, several studies have reported 
beneficial effects of sulfasalazine, an inhibitor of systemic Xc−-
mediated cystine uptake (92, 93). However, in a small clinical 
trial, sulfasalazine was without benefit in recurrent glioblastoma 
(94). In addition, sulfasalazine did not improve the outcomes of 
combined temozolomide and radiotherapy in patients with newly 
diagnosed glioblastoma (95). This therapeutic failure may be due 
to Nrf2-mediated upregulation of Xct induced by temozolomide 
(96), offsetting the inhibitory effects of sulfasalazine (92). Erastin, 
another Xct inhibitor, was reported to be superior to sulfasalazine 
for induction of cell death when administered in combination 
with temozolomide to C6 glioma cells, owing to its ability to 
decrease the expression of the Nrf2-induced transsulfuration 
enzyme cystathionine-γ-lyase (92), thereby depleting GSH for-
mation via two mechanisms.
Inhibition of GSH synthesis can be compensated for by Nrf2-
induced upregulation of the NADPH-dependent thioredoxin 
pathway (20). However, combined treatment with inhibitors of 
GSH synthesis (e.g., buthionine sulfoximine) and thioredoxin 
reductase (e.g., auranofin) decreased tumor survival in A172 
glioblastoma cells (20). Although a combination of GSH and 
thioredoxin pathway inhibitors was efficacious in  vitro, it may 
be unsuitable for patients considering the potential safety and 
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tolerability of this combination. However, it may be possible to 
limit its toxicity by utilizing targeted drug delivery techniques.
ConCLUsion
We have discussed the roles of redox and epigenetic regulation 
in glioblastoma. The findings described here suggest that glio-
blastoma is sustained by an intricate network of Nrf2, receptor 
tyrosine kinases, cobalamins and cobalamin-dependent enzymes, 
along with the D4 receptor and other factors, such as cystine/
cysteine transporters and TET enzymes (Figure  5). Mutations 
in receptor tyrosine kinases or their downstream targets can 
result in hyperactivity of the PI3K and ERK pathways, leading to 
constitutively higher Nrf2 activity. Higher Nrf2 activity induces 
overexpression of genes involved in antioxidant production, such 
as cystine/cysteine transporters and promotes 2-HG formation 
in IDH1 mutants. Nrf2 can also upregulate its own activity by 
promoting p62 transcription. The excessively reduced redox 
state of glioblastoma cells enhances the uptake and processing of 
cobalamins and promotes the activity of redox-sensitive proteins 
(i.e., HDAC2). In methionine-independent cells, the cobalamin-
dependent enzyme, MS, enhances the formation of SAM, which 
influences methyltransferase activity. The other cobalamin-
dependent enzyme in humans, MCM, promotes the formation 
of oncometabolites, affecting a wide range of proteins, including 
TET1-3, KDM2-7, prolyl hydroxylases, and Keap1. D4 receptors 
may contribute to this network by regulating MS activity via 
stimulation of the ERK/PI3K pathways, either directly or indi-
rectly by transactivation of PDGFRβ. These interactions result 
in an amalgamation of epigenetic changes, which contribute to 
the induction of the cancer phenotype and drive tumor growth. 
Indeed, the model described for glioblastoma can be applied to 
all cancers, and we hope that the novel concepts presented here 
will spur new research in this context.
Although existing treatment options for glioblastoma have not 
achieved clinically meaningful remission rates, epigenetic- and 
redox-modifying agents may augment the repertoire of available 
life-saving drugs. HDAC inhibitors have demonstrated utility 
in treating certain forms of cancer. However, these drugs may 
reactivate a DNA repair mechanism in glioblastoma. BET inhibi-
tors may be immune to this unwanted effect of HDAC inhibitors. 
Luteolin and related drugs may sensitize glioblastoma cells to the 
effects of radiotherapy or chemotherapy and mitigate damage to 
surrounding neurons and non-cancerous glia. The ability of D4 
receptor antagonists to induce growth arrest and apoptosis of stem 
cells is an encouraging development and suggests that a better 
understanding of the relationships between cancer metabolism, 
redox status, and epigenetics may lead to significantly higher 
remission rates. Mutations in redox and methylation pathway 
genes may complement canonical mutations for existing glioblas-
toma subtypes and could be incorporated into a panel for phar-
macogenomic screening for the optimization of drug treatment. 
We envision an expansion in the near future of drugs targeting 
antioxidant production and related biochemical and molecular 
pathways, offering hope of improved treatment outcomes for 
glioblastoma.
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